Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Association Areas of the Cortex01:21

Association Areas of the Cortex

Association areas are regions of the cerebral cortex that do not have a specific sensory or motor function. Instead, they integrate and interpret information from various sources to enable higher cognitive processes such as memory, learning, and decision-making. Some key association areas include the following:
Prefrontal Association Area: This area is located in the frontal lobe and is involved in planning, decision-making, and moderating social behavior. It connects with primary motor areas,...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

REFCOR guidelines for sinonasal adenocarcinoma.

European annals of otorhinolaryngology, head and neck diseases·2026
Same author

Sinonasal mucosal melanoma: REFCOR guidelines for diagnosis, treatment and follow-up.

European annals of otorhinolaryngology, head and neck diseases·2026
Same author

Phase II study of magrolimab combination therapies in patients with head and neck squamous-cell carcinoma.

ESMO open·2026
Same author

REFCOR guidelines for sinus and nasal cavity cancer.

European annals of otorhinolaryngology, head and neck diseases·2026
Same author

A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM).

ESMO open·2025
Same author

Retrospective multicentric survival analysis of patients receiving TPEx regimen as first-line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma.

ESMO open·2025
Same journal

Measuring antidepressant side effects in military personnel - Clinical validation of the French version of the UKU-SERS-Pat Scale: A comparative study of patient and clinician ratings.

L'Encephale·2026
Same journal

[Empowerment in addictology].

L'Encephale·2026
Same journal

Evaluation of the links between smoking and conspiracy mentality.

L'Encephale·2026
Same journal

Use of a relevance assessment tool in therapeutic residential care: A real world study.

L'Encephale·2026
Same journal

Prevalence and characteristics of domestic violence in a sample of adult psychiatric outpatients: A cross-sectional study.

L'Encephale·2026
Same journal

From representations to practice: how professionals describe supporting parents with psychiatric or somatic illness or disability.

L'Encephale·2026
See all related articles

Related Experiment Video

Updated: Jul 1, 2026

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

[Frontotemporal dementia: a review].

V Chauvire1, C Even, J Thuile

  • 1Clinique des maladies mentales et de l'encéphale, centre hospitalier Sainte-Anne, 100, rue de la Santé, 75674 Paris cedex 14, France.

L'Encephale
|September 16, 2008
PubMed
Summary
This summary is machine-generated.

Frontotemporal dementia (FTD) is a progressive neurological disorder affecting the frontal and temporal lobes. Early diagnosis using clinical, neuropsychological, and imaging data is crucial for management, though treatments focus on symptoms rather than halting degeneration.

More Related Videos

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
08:29

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

Related Experiment Videos

Last Updated: Jul 1, 2026

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
08:29

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

Area of Science:

  • Neurology
  • Neuroscience
  • Pathology

Context:

  • Frontotemporal dementia (FTD) is a progressive neurodegenerative disorder impacting the frontal and anterior temporal cortex.
  • FTD presents with psychiatric symptoms, behavioral changes, memory impairment, and speech disturbances, necessitating differential diagnosis from conditions like late-onset schizophrenia.
  • Consensus criteria aid in clinical diagnosis, with onset typically in the fifth or sixth decade.

Purpose:

  • To outline the clinical characteristics, diagnostic approaches, and current therapeutic strategies for Frontotemporal Dementia (FTD).
  • To highlight the importance of early identification through cognitive evaluation and neuroimaging.
  • To discuss the pathophysiological underpinnings, including the role of tau protein.

Summary:

  • Clinical presentation involves behavioral and personality changes, dysexecutive syndrome identified by tools like the FAB, and distinct neuropsychological patterns compared to Alzheimer's disease.
  • Neuroimaging, including MRI and functional imaging, aids in diagnosis by revealing frontal lobe abnormalities.
  • Pathophysiology involves tau protein abnormalities, as seen in Pick's disease, and genetic contributions.

Impact:

  • Early and accurate diagnosis of FTD enables appropriate management, focusing on symptomatic treatment with serotonergic agents and supportive care for patients and caregivers.
  • While current treatments manage behavioral symptoms, they do not halt disease progression.
  • FTD management requires tailored approaches due to the younger age of onset and significant behavioral disturbances, often leading to rapid autonomy loss and institutionalization.